About Vaccinex

Vaccinex is a privately held biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. We conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs.

Learn More 

Therapeutic Antibodies

Oncology BVX20
  VX15
  VX35
  VX70
Multiple Sclerosis VX15
Autoimmune Disease VX5
  VX30

NKT Cell Platform

Oncology VX25 Vaccine
Autoimmune Disease VX45
Infectious Disease VX25 Vaccine

Technology Platform

Vaccinex has developed one of only a handful of major, commercial platforms for human antibody discovery. Our core technology provides for robust expression of full length IgG in mammalian cells and, when coupled with high-throughput selection, allows for the rapid identification of fully human monoclonal antibodies.

Learn More